OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
January 18, 2017
Daiichi Sankyo has closed its Mumbai, India research division as part of the company’s strategy to narrow its focus to cancer research, India's Economic Times reports. The Daiichi Sankyo India Pharma Limited (DSIN) was established in 2007 and employs about 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline will be transferred to Daiichi Sankyo’s R&D Division. http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/daiichi-shuts-india-rd-division/articleshow/56486750.cms